CASI Pharmaceuticals to Participate at Guggenheim Healthcare Innovation Conference
-
Sunderland inflict more derby pain on Newcastle
-
Nepali youth demand release of govt report into deadly September uprising
-
US, Iran trade threats to target infrastructure in Middle East
-
Paris doubles up with super-G victory at World Cup finals
-
Dortmund part ways with sporting director Kehl
-
Russia resumes use of space launch site damaged in accident
-
Cuba scrambles to restore power after new blackout
-
Senegal's Idrissa Gueye ready to 'hand back' AFCON medals
-
New Zealand's Walsh bags fourth world indoor gold
-
Goggia claims first super-G title after victory in Kvitfjell
-
Slovenia votes in tight polls, with conservatives eyeing comeback
-
A herd stop: Train kills 3 rare bison in Poland
-
Vietnam, Russia to sign energy deal: Hanoi
-
American Gumberg triumphs in Hainan for second DP World Tour win
-
South Africa clinch 19-run win over New Zealand in fourth T20
-
Iran threatens Middle East infrastructure after Trump ultimatum
-
French elect mayors in key cities including Paris
-
'They beat us with whips': Sudan RSF detainees tell of horrors in El-Fasher
-
Australia's Hannah Green wins historic third tournament in a row
-
China's premier vows to expand global 'trade pie': state media
-
Belgium commemorates Brussels attacks 10 years on
-
Sri Lanka raises fuel prices by 25 percent as war bites
-
Rights groups fear use of arrest to stifle free speech in Pakistan
-
Iranian missiles sow panic, destruction in Israeli towns
-
Damaged Russian tanker to be towed to Libya: state-owned company
-
Gilgeous-Alexander scores 40, LeBron breaks NBA appearance record
-
Cuba hit by second nationwide blackout in a week
-
BTS draws over 100,000 fans to Seoul comeback concert: label
-
US-China 'Board of Trade' may help ties but experts flag market worries
-
Sinner, defending champ Mensik advance to third round at Miami Open
-
Iran missile strikes wound over 100 in two south Israel towns
-
Shai hits 40 as Thunder win despite NBA melee with four ejected
-
Records shattered as US heatwave moves eastward
-
Iran missiles hit southern Israel, injuring more than 100
-
LeBron James breaks record for most NBA games played
-
'Perfect' PSG sweep past Nice to reclaim top spot in Ligue 1
-
Japan coach says Asian Cup crown 'well-deserved' for inspirational team
-
PSG sweep past Nice to reclaim top spot in Ligue 1
-
Robert Mueller, ex-FBI chief who led Trump-Russia probe, dead at 81
-
Milan move to within five points of Serie A leaders Inter
-
Duplantis masterclass as Kerr and record-setter Ehammer shine
-
Rosenior urges Chelsea to 'forget the noise' after damaging loss
-
Marquez ambushed Di Giannantonio to win Brazil sprint
-
Sweden's Duplantis wins fourth world indoor pole vault title
-
Liverpool, Chelsea slip up in Champions League race
-
WHO sends first overland convoy from emergencies hub to Beirut
-
Everton rub salt in Chelsea wounds as Champions League race tightens
-
Coach Mignoni returns but Toulon crash to Stade Francais
-
Robert Mueller, ex-FBI chief who led Trump-Russia inquiry, dead at 81
-
Sinner and Pegula advance to third round at Miami Open
CASI Pharmaceuticals to Participate at Guggenheim Healthcare Innovation Conference
SOUTH SAN FRANCISCO, CALIFORNIA / ACCESS Newswire / November 4, 2025 / CASI Pharmaceuticals, Inc. (NASDAQ:CASI), a clinical-stage biopharmaceutical company focused on developing CID-103, a potential best-in-class, anti-CD38 monoclonal antibody for patients with organ transplant rejection and autoimmune diseases, today announced that the CASI management team will participate at the Guggenheim Healthcare Innovation Conference 2025 in a fireside chat at 9:30 AM ET on November 12 in Boston, MA. CASI will also host one-on-one meetings with investors at the conference.
About CASI Pharmaceuticals
CASI Pharmaceuticals, Inc. is a public biopharmaceutical company developing CID-103, an anti-CD38 monoclonal antibody for organ transplant rejection and autoimmune diseases.
CID-103 is a fully human IgG1, potentially best-in-class, clinical stage, anti-CD38 monoclonal antibody which targets a unique epitope and has demonstrated an encouraging pre-clinical efficacy and clinical safety profile compared to other anti-CD38 monoclonal antibodies, and for which CASI owns exclusive global rights. CASI received FDA IND clearance to conduct a Phase 1 study in renal allograft antibody-mediated rejection (AMR) in the U.S. and plans for first patient in first quarter of 2026. In parallel, CASI is actively recruiting and dosing patients in an ongoing Phase 1 study in immune thrombocytopenia (ITP). In addition, CASI is assessing multiple technologies for development of a stable, high concentration protein solution for subcutaneous injection.
More information on CASI is available at www.casipharmaceuticals.com.
INVESTOR CONTACT:
Ingrid Choong, PhD
650-619-6115
[email protected]
SOURCE: CASI Pharmaceuticals
View the original press release on ACCESS Newswire
O.M.Souza--AMWN